初诊帕金森病帕金森进展标志物倡议参与者中非运动症状的药物治疗使用。
Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants.
机构信息
Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
出版信息
J Parkinsons Dis. 2020;10(3):1239-1243. doi: 10.3233/JPD-201973.
Parkinson's disease (PD) patients experience a range of non-motor symptoms that are believed to be related to disease pathophysiology, many of which are treatable by medications. Among newly-diagnosed PD participants in the Parkinson's Progression Markers Initiative study, we describe (1) the frequency of medication use for common non-motor symptoms, and (2) when non-motor symptomatic treatment was initiated relative to PD diagnosis. Non-motor medication use was reported by 73% of participants, most commonly for depression, constipation, and anxiety. Treatment of some non-motor symptoms, notably depression, antedated diagnosis. These data may be useful for studies of non-motor symptoms in PD.
帕金森病（PD）患者经历一系列被认为与疾病病理生理学相关的非运动症状，其中许多症状可以通过药物治疗。在帕金森进展标志物倡议研究中，我们描述了（1）新发 PD 患者使用药物治疗常见非运动症状的频率，以及（2）非运动症状治疗相对于 PD 诊断的起始时间。73%的参与者报告了非运动药物的使用，最常见的是用于治疗抑郁、便秘和焦虑。一些非运动症状的治疗，特别是抑郁，早于诊断。这些数据可能对 PD 中非运动症状的研究有用。
Zotero 插件